Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation

Thrombosis and Haemostasis

Volumn 108, Issue 3, 2012, Pages 561-569

  Borgman, Mark P ^a   Pendleton, Robert C ^b   McMillin, Gwendolyn A ^c,d   Reynolds, Kristen K ^a   Vazquez, Sara ^b   Freeman, Andrew ^b   Wilson, Andrew ^c   Valdes, Roland ^a,e   Linder, Mark W ^a,e  

^a PGXL Laboratories   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c ARUP LABORATORIES   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e University of Louisville School of Medicine   (United States)

Author keywords

Algorithm; Anticoagulation; Clinical trial; Pharmacogenetics; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; ENZYME; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

ACCURACY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; DOSE CALCULATION; DRUG DETERMINATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE DRUG DOSE; MALE; MEDICATION THERAPY MANAGEMENT; PILOT STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 84865825594     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-03-0159     Document Type: Article

References (32)

1. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645-649.
2. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293.
3. Zhu Y, Shennan M, Reynolds KK, et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem 2007; 53: 1199-1205.
4. Voora D, Eby C, Linder MW, et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 2005; 93: 700-705.
5. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-719.
6. Margaglione M, Colaizzo D, D'Andrea G, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84: 775-778.
7. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. J Am Med Assoc 2002; 287: 1690-1698.
8. Linder MW, Looney S, Adams JE, 3rd, et al. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis 2002; 14: 227-232.
9. Bon Homme M, Reynolds KK, Valdes R, Jr., et al. Dynamic pharmacogenetic models in anticoagulation therapy. Clin Lab Med 2008; 28: 539-552.
10. Linder MW, Bon Homme M, Reynolds KK, et al. Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy. Clin Chem 2009; 55: 1861-1868.
11. Bodin L, Verstuyft C, Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106: 135-140.
12. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-2333.
13. Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Human Mol Gen 2005; 14: 1745-1751.
14. Scordo MG, Pengo V, Spina E, et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002; 72: 702-710.
15. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40: 587-603.
16. Linder MW, Moyer T, Reynolds, KK, et al. Pharmacogenetic modeling to predict and avoid above range INR measurements. Clin Chem 2009; 55: A224 (Abstract).
17. Kovacs MJ, Rodger M, Anderson DR, et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, doubleblind, controlled trial. Ann Intern Med 2003; 138: 714-719.
18. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 160S-198S.
19. Henne KR, Gaedigk A, Gupta G, et al. Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype. J Chromatogr B (Biomed Sci Appl) 1998; 710: 143-148.
20. Rosendaal FR, Cannegieter SC, van der Meer FJ, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.
21. Gage BF, Eby CS. Pharmacogenetics and anticoagulant therapy. J Thromb Thrombolysis 2003; 16: 73-78.
22. Reynolds K, Valdes Jr R, Hartung B, et al. Individualizing warfarin therapy. Personal Med 2007; 4: 11-31.
23. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007; 116: 2563-2570.
24. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008; 83: 460-470.
25. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 1993; 118: 511-520.
26. Kamali F, Pirmohamed M. The future prospects of pharmacogenetics in oral anticoagulation therapy. Br J Clin Pharmacol 2006; 61: 746-751.
27. Beyth RJ, Milligan PE, Gage BF. Risk factors for bleeding in patients taking coumarins. Curr Hematol Rep 2002; 1: 41-49.
28. Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 2010; 55: 2804-2812.
29. Anderson JL, Horne BD, Stevens SM, et al. A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II). Circulation 2012; 125: 1997-2005.
30. Gong IY, Tirona RG, Schwarz UI, et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 2011; 118: 3163-3171.
31. McMillin GA, Melis R, Wilson A, et al. Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study. Ther Drug Monit 2010; 32: 338-345.
32. Hillman MA, Wilke RA, Yale SH, et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res 2005; 3: 137-145.